Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Non-Current Liabilities (2016 - 2025)

Sunshine Biopharma's Total Non-Current Liabilities history spans 9 years, with the latest figure at $596785.0 for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 19.86% year-over-year to $596785.0; the TTM value through Dec 2025 reached $596785.0, down 19.86%, while the annual FY2025 figure was $596785.0, 19.86% down from the prior year.
  • Total Non-Current Liabilities reached $596785.0 in Q4 2025 per SBFM's latest filing, down from $636708.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $1.9 million in Q4 2021 to a low of $489027.0 in Q3 2024.
  • Average Total Non-Current Liabilities over 5 years is $715793.0, with a median of $638295.0 recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: tumbled 63.93% in 2022, then surged 38.09% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $1.9 million in 2021, then crashed by 63.93% to $685264.0 in 2022, then decreased by 14.23% to $587764.0 in 2023, then grew by 26.7% to $744724.0 in 2024, then decreased by 19.86% to $596785.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Total Non-Current Liabilities are $596785.0 (Q4 2025), $636708.0 (Q3 2025), and $706530.0 (Q2 2025).